Innovita Biological Technology Co Ltd
SSE:688253
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
29.02
41.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Innovita Biological Technology Co Ltd
Income from Continuing Operations
Innovita Biological Technology Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innovita Biological Technology Co Ltd
SSE:688253
|
Income from Continuing Operations
ÂĄ246.9m
|
CAGR 3-Years
27%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Income from Continuing Operations
ÂĄ2.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Income from Continuing Operations
ÂĄ428.3m
|
CAGR 3-Years
33%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Income from Continuing Operations
ÂĄ740.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Income from Continuing Operations
ÂĄ1.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Income from Continuing Operations
ÂĄ1.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
Innovita Biological Technology Co Ltd
Glance View
Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 439 full-time employees. The company went IPO on 2022-07-28. The firm's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.
See Also
What is Innovita Biological Technology Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
246.9m
CNY
Based on the financial report for Dec 31, 2024, Innovita Biological Technology Co Ltd's Income from Continuing Operations amounts to 246.9m CNY.
What is Innovita Biological Technology Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
63%
Over the last year, the Income from Continuing Operations growth was 42%. The average annual Income from Continuing Operations growth rates for Innovita Biological Technology Co Ltd have been 27% over the past three years , 63% over the past five years .